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ABSTRACT
Leptin functions through a well-documented central neu-
roendocrine pathway to regulate bone mass. However, the
ability of leptin to modulate bone mass through a periph-
eral mechanism has been debated due to conflicting in
vitro results and lack of sufficient in vivo models. We uti-
lized mice with LoxP sites introduced into the long-form
leptin receptor (ObRb) gene to determine how leptin regu-
lates mesenchymal progenitor cell (MPC) differentiation
and osteoblast function in vitro and in vivo. Rapid phos-
phorylation of Stat3 after leptin treatment of bone mar-
row stromal cells (BMSCs) from mice with conditional
deletion of ObRb in macrophages (LysM
Cre1F/F
) con-
firmed expression of functional leptin receptors by
BMSCs. Adenovirus-Cre mediated disruption of ObRb in
primary stromal cells decreased mineralization and
increased adipogenesis. In contrast, BMSCs harvested
from leptin-signaling deficient Ob/Ob or Db/Db mice
showed increased mineralization. To determine the physio-
logic relevance of these differences, mice with cell-specific
deletion of ObRb in mesenchymal precursors (3.6Cre1F/F)
or osteoblasts (2.3
Cre1F/F
) were generated. Although the
2.3
Cre1F/F
mice were grossly normal, the 3.6
Cre1F/F
mice
displayed mild obesity that was not attributed to food
intake. Femurs of 3.6
Cre1F/F
animals showed a 58%–
61.9% increase in trabecular bone volume and a 65.5%–
74% increase in bone mineral density. Cortical volume
and mineral content were also increased 18%–22%. Pri-
mary 3.6Cre1F/F BMSCs recapitulated the high mineraliza-
tion phenotype of Ob/Ob and Db/Db BMSCs. We
conclude that leptin may have multiple peripheral roles
depending on the differentiation state of MPC. Leptin (a)
helps maintain MPCs in an undifferentiated state and (b)
promotes mineralization of more differentiated osteoblasts.
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INTRODUCTION
Leptin, named after the Greek ‘‘leptos’’ meaning ‘‘thin,’’ was
discovered in 1994 during the analysis of a colony of sponta-
neously obese mice [1]. This 16 kDa cytokine was later found
to play a prominent role in regulation of energy metabolism
and appetite [2–4]. Many secondary functions of leptin have
also been uncovered [5], including modulation of immune
cell responses [6] and maintenance of bone mass [7–9]. The
ability of leptin to regulate bone formation through peripheral
mechanisms has been debated due to conflicting in vitro
results and a lack of sufficient in vivo models. The challenge
to study leptin’s peripheral effects with conditional regulated
gene recombination (Cre-LoxP) systems was proposed in
1998 [10], but these experiments were not possible until the
recent generation of a mouse model with LoxP sites flanking
the Jak2 signaling component of the long-form leptin receptor
(ObRb) [11]. To help clarify the controversy of leptin’s pe-
ripheral actions on bone through regulation of mesenchymal
progenitor cell (MPC) differentiation and osteoblast function,
we have used this model and generated three cell-specific
knockouts of ObRb using LysM-Cre (macrophage), Col2.3-
Cre (osteoblast), and Col3.6-Cre (MPC) mice.
Previous research demonstrates two mechanisms of leptin
regulation of bone mass. First, elegant in vivo studies support
the central hypothesis which states that binding of leptin to
ObRb in the hypothalamus can stimulate bone loss by regulat-
ing osteoblast activity through the sympathetic nervous sys-
tem [7, 12, 13]. Conversely, the peripheral hypothesis postu-
lates that there are mechanisms through which local leptin
can directly regulate bone formation by acting on cells in the
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bone marrow. The existence of such mechanisms has been
explored by multiple groups who have compiled key pieces
of evidence. For example, leptin receptors are expressed on
the surface of human bone marrow stromal cells (BMSCs)
[14] and recombinant leptin stimulation of human BMSCs in
vitro has been shown to promote mineralization and partly in-
hibit adipogenic differentiation [15]. It has further been dem-
onstrated in vitro that BMSC fate decisions can be regulated
by suppression of leptin expression after addition of adipo-
genic factors [16]. Last, in vivo, peripheral (subcutaneous or
intraperitoneal) delivery of supra-physiologic doses of leptin
to leptin-deficient Ob/Ob mice resulted in a >30% increase in
fluorochrome-labeled tibial endosteal surface and an 84.2%
increase in distal femoral trabecular mineral content, respec-
tively [8, 9]. Despite this evidence, the existence of physiolog-
ically relevant peripheral mechanisms is debated due to con-
flicting studies that have failed to demonstrate pro-osteogenic
effects of leptin stimulation of primary mouse osteoblast cul-
tures [7] and one in vivo publication with osteoblast-specific
ObRb deletion that lacked significant differences in vertebral
bone mass [17]. Although conflicting, these studies have laid
the groundwork for a more in-depth examination of leptin’s pe-
ripheral actions with additional delineation of effects on primi-
tive MPCs and more differentiated osteoblast populations.
The true mesenchymal stem cell (MSC) is an elusive in
vivo precursor to mesenchymal lineage cells such as osteo-
blasts, adipocytes, and chondrocytes. MSCs have been identi-
fied in tissues including bone marrow [18], adipose [19], and
dental pulp [20]. Although many groups have focused on
characterizing the MSC, specific cell surface markers have
not been identified [21, 22]. Thus, our methods for in vitro
isolation date back to the 1970s [18, 23] and rely on the ad-
herence of a subpopulation of cells to tissue culture plastic
and subsequent passaging to enrich for MSCs [24]. in vivo
the MSC is defined as a multipotent cell that undergoes self-
renewal until stimulated to differentiate into a daughter line-
age. Culturing these cells in vitro results in cells that are
more differentiated and proliferative, yet not fully lineage
committed. Thus, studies which disrupt gene expression in
vitro may result in a phenotype that is different than effects
found when the gene is deleted in vivo. In recognition of the
limited knowledge of the ‘‘true’’ MSC, this report will use the
term MPC to refer to the in vivo precursor populations tar-
geted by Col3.6-Cre and BMSCs or adipose-derived stromal
cells (ADSCs) to refer to MSCs that have been isolated and
cultured in vitro.
Analysis of current models of leptin signaling deficiency
such as the Ob/Ob mouse (leptin deficient) and the Db/Db
mouse (ObRb deficient) are limited by secondary complica-
tions of diabetes and obesity. Mutant mice display a pheno-
type of uncontrolled eating and rapid weight gain. They also
exhibit hyperphagia, glucose intolerance, elevated plasma in-
sulin, subfertility, impaired wound healing, and both low
(femoral) and high (vertebral) trabecular bone mass [25, 26].
To circumvent these systemic complications, we utilized a
mouse model with LoxP sites flanking exon 17 of the ObRb
gene, deletion of this gene segment by Cre recombinase ter-
minates receptor function [11]. This study was designed to
critically evaluate the ability of leptin to modulate differentia-
tion of MPCs and the function of their osteoblast progeny.
We hypothesized that leptin exerts differential effects on line-
age committed cells such as osteoblasts when compared with
their more primitive MPC precursors. To clarify these differ-
ences, we have used in vitro adenovirus Cre and in vivo
Col2.3-Cre (osteoblast) and Col3.6-Cre (MPC) mediated
recombination of ObRb to explore the inherent role of physio-
logic, circulating leptin in bone formation and maintenance.
EXPERIMENTAL PROCEDURES
Primary Cell Culture
BMSCs were harvested as described previously [27] with
slight modification. Femora, tibiae, and humeri were dissected
free of surrounding muscle. Marrow was removed with phos-
phate buffered saline (PBS) and filtered through a 70-lm cell
filter. The marrow content of 6–9 bones was plated into a
75-cm2 culture flask in BMSC growth medium (a-Modified
Eagle’s Medium [a-MEM; Invitrogen, Carlsbad, CA, http://
www.invitrogen.com/Gibco, Grand Island, NY, http://www.
invitrogen.com], 10% fetal bovine serum [Gibco, Grand
Island, NY, http://www.invitrogen.com; Lot no. 451459], 100
U/ml penicillin, 100 mg/ml streptomycin sulfate [Gibco,
Grand Island, NY, http://www.invitrogen.com; Cat: 15140],
100 nm dexamethasone [Sigma, St. Louis, MO, www.
sigmaaldrich.com; Cat: D8893]). To harvest ADSCs intra-ab-
dominal and paralumbar fat pads were collected, washed with
PBS, and minced. Minced adipose was incubated for 1 hour
at 37C in a-MEM þ 0.2% CollagenaseII (Gibco, Grand
Island, NY, http://www.invitrogen.com; Cat: 17101). ADSCs
were pelleted at 1,100 rpm for 10 minutes at 4C and plated
at 6–8 million cells per 10 cm plate in ADSC growth medium
(Dulbecco’s Modified Eagle Medium [DMEM; Invitrogen/
Gibco, Grand Island, NY, http://www.invitrogen.com], 10%
fetal bovine serum [Gibco, Grand Island, NY, http://www.
invitrogen.com; Lot no. 451459], 100 U/ml penicillin, 100
mg/ml streptomycin sulfate). Cells were cultured at 37C in
an atmosphere of 100% humidity and 5% CO2. Colonies of
adherent cells were formed by 11–14 days. The colonies were
harvested and the subcultured cells were replated at 15,000
cells per square centimeter.
PCR
RNA was harvested using Trizol reagent (Invitrogen, Freder-
ick, MD, www.invitrogen.com; Cat: 15596) and 0.3–1 lg of
total RNA was processed using the SuperScript First-Strand
RT-PCR kit (Invitrogen, Frederick, MD, www.invitrogen.com;
Cat: 12371) to generate cDNA. Leptin receptor expression
was analyzed as previously reported [28]. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) primers were used as a
loading control, GAPDH_F: TTCCAGTATGACTCCACTCA
CGGCAAAT; GAPDH_R: TGGTGAAGACACCAGTAGAC
TCCACGAC. Genomic DNA was harvested using the
DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany,
http://www.qiagen.com; Cat: 69506). Expression of osteocal-
cin was determined with computed threshold method qPCR
using SYBR Green PCR master mix (Applied Biosystems,
Foster City, CA, www.appliedbiosystems.com; Cat: 4309155)
with GAPDH as a loading control. OCN_F: CAAGCAGGGT-
TAAGCTCACA; OCN_R: GGTAGTGAAC AGACTCCGGC;
GAPDH_F: TGAAGCAGGCATCTGAGGG; GAPDH_R:
CGAAGGTGGAAGAGTGGGAG.
Western Blot
Protein was harvested using Nonidet (TM) P40 lysis buffer
(10% glycerol, 1% Nonidet P40, 50 mM Tris pH 7.4, 200
mM NaCl, 2 mM MgCl2, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF), 1 Protease Inhibitor Cocktail [Sigma, St.
Louis, MO, www.sigmaaldrich.com; Cat: P8340]) þ phospha-
tase inhibitors (Roche. Indianapolis, IN, www.roche.com; Cat:
04906845001). Cells were washed with cold PBS þ phospha-
tase inhibitors, collected and pelleted at 4C. Cell pellets
were resuspended in 50–100 ll of lysis buffer and incubated
for 30 minutes on ice. Protein concentration was measured at
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595 nm with Bio-Rad protein assay dye concentrate (Cat:
500-0006). Protein extracts (50 lg) were boiled in 2 sodium
dodecyl sulfate (SDS) sample buffer 10 minutes and separated
on a 10% Tris-HCl polyacrylamide gel (Bio-Rad, Hercules,
CA, http://www.bio-rad.com). Protein was transferred to poly-
vinylidene fluoride (PVDF) membranes using a wet transfer
system (Bio-Rad; Cat: 170-3930). Membranes were blocked
in 5% milk (Bio-Rad Cat: 170-6404) 1 hour and probed over-
night with 1:500 Stat3 (Cell Signaling Technology, Beverly,
MA, http://www.cellsignal.com; Cat: 9132), 1:500 P-Stat3
(Cell Signaling Cat: 9131), or 1:1,000 GAPDH (Chemicon
International, Temecula, CA, http://www.chemicon.com; Cat:
MAB374). Signals were amplified with 1:1,500 horse radish
peroxidase-conjugated secondary antibody (Santa Cruz Bio-
technology Inc., Santa Cruz, CA, http://www.scbt.com) and
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific, Pierce Product, Rockford, IL, www.piercenet.com)
and developed using film exposure.
Adenoviral Transduction
P1 BMSCs were plated at a density of 15,000 cells per square
centimeter in T75 flasks. After 4 hours, virus was added at
800 multiplicity of infection (MOI) for BMSC or 400 MOI
for ADSC in 4 ml a-MEM þ 0.5% FBS. Complete media
was added after 4 hours. Adenovirus was used in accordance
with NIH guidelines and obtained from the University of
Michigan vector core (Ann Arbor, MI). Adenovirus-express-
ing cre recombinase, harvest date February 19, 2009, viral ti-
ter 2.40E11 plaque forming unit (PFU) per milliliter. Adeno-
virus CMVpLpA.dlE3 #1 (AdBlank), harvest date February
18, 2001, viral titer 1.30E11 PFU per milliliter.
in vitro Mineralization Assay
Primary BMSCs in passage 2–3 were used for this assay.
Cells were plated in 12-well or 6-well plates at 25,000–
30,000 cells per square centimeter. Plated cells were allowed
to grow to confluence in complete medium for 2–4 days. Af-
ter reaching confluence cells were cultured in osteogenic me-
dium (BMSC Growth Medium þ 100 nm dexamethasone
[Sigma; Cat: D8893], 10 mM b-glycerophosphate [Sigma;
Cat: G9891], and 50 lm ascorbic acid 2-phosphate [Sigma;
Cat: A8960]) for up to 14 days. Cells were fixed with 70%
ethanol at 4C for 1 hour, rinsed with water, stained for
10 minutes in 40 mM, pH 4.2 alizarin red, and washed exten-
sively with water. Dye was eluted in 10% w/v hexadecylpyri-
dinium chloride monohydrate (Wako, Chemical, Osaka,
Japan, http://www.wako-chem.co.jp/english) in 10 mM
sodium phosphate pH 7.0 and concentration determined by
absorbance measurement at 562 nm.
in vitro Adipogenic Differentiation
ADSCs were plated at 30,000 cells per square centimeter and
grown to confluence for 2 days. Cells were induced with adi-
pogenic medium (ASC Growth Medium þ 50 lM Isobutyl-
methylxanthine [Sigma; Cat: I7018], 1 lM dexamethasone
[Sigma; Cat: D8893), 167 nM insulin [Sigma; Cat: I5500],
and 5 lg/ml Troglitazone [Cayman Chemical, Ann Arbor,
MI, www.caymanchem.com; Cat: 71750]) for 2 days. Adipo-
genic maintenance media (ADSC Growth Medium þ 167 nM
insulin [Sigma; Cat: I5500]) was then added for 2 days. This
process of induction media followed by maintenance media
was repeated once. Cells were then fixed in zinc buffered for-
malin (Z-fix, Anatech LTD, Battle Creek, MI, www.anatechltdusa.
com) for 1 hour and stained with Oil Red O solution (Sigma;
Cat: O0625). Dye was eluted in 100% isopropanol and quanti-
fied at 500 nm.
Animals
All procedures were approved by the University Committee
on the Use and Care of Animals (UCUCA). Col2.3-Cre and
Col3.6-Cre mice were obtained from Dr. Fei Liu (University
of Michigan) [29]. LysM-Cre mice were obtained from Jack-
son Laboratory (Bar Harbor, Maine, www.jax.org; Cat:
004781) [30]. Flox/Flox Jak2-ObRb mice were obtained from
Dr. Martin Myers (University of Michigan) with permission
of Dr. Streamson Chua (Columbia University) [11]. Breeding
cages contained one male with two females. Pups were geno-
typed via PCR analysis of tail biopsy DNA with primers as
reported previously [11]. Deletion of the floxed allele was
determined using the three-primer system designed by
McMinn et al. [11]. Analysis of food intake was performed
daily for 1 week. Mice were housed 2–3 animals per cage,
mass of chow was determined every 24 hours, chow intake
was averaged per housed animals to determine daily intake.
Blood Collection and Serum Analysis
Blood was collected from the mice by nicking the lateral tain
vein and pooling blood drops into BD Microtainer tubes
(Franklin Lakes, NJ, www.bdbiosciences.com). Blood was
allowed to clot at room temperature for 30–45 minutes. Sam-
ples were spun at 3,000 rpm for 10 minutes at 4C and serum
supernatant removed. Analysis of serum chemistries was per-
formed by the Animal Diagnostic Laboratory of the University
of Michigan (Ann Arbor, MI). For glucose and cholesterol
analyses, animals were placed on a 6 hours fast before serum
collection. Leptin analysis was performed using an ELISA
assay kit as described for serum leptin (R&D Systems Inc.,
Minneapolis, http://www.rndsystems.com; Cat: MOB00).
MicroCT
Femurs were wrapped in 70% ethanol-soaked gauze and
scanned using a vivaCT 40 lCT system (Scanco Medical,
Switzerland) with an isotropic voxel size of 10.5 lm (55 kVp,
145 lA, 1,000 projections per 180, 200 milliseconds integra-
tion time). 2D transverse slices were reconstructed into 2,048
 2,048 pixel matrices. Cortical bone parameters were meas-
ured by analyzing 50 slices (0.525 mm) of the mid-diaphysis.
This region was defined to be the central portion between the
proximal and distal ends of the femur. A semi-automated con-
touring method was used to determine the outer cortical bone
perimeter. Briefly, a user-defined contour was drawn around
the cortical bone perimeter of the first slice. This initial esti-
mate is then subjected to automated edge detection. This
semi-automated contour then serves as the initial estimate for
the second slice, and the automated contouring process con-
tinues for all 50 slices. A fixed, global threshold of 375
(1/1,000 gray scale) corresponding to 635.9 mg of hydroxyap-
atite (HA) per milliliter was used to distinguish cortical bone
from soft tissue and marrow. Trabecular bone parameters
were measured by analyzing 101 slices (1.06 mm) of the dis-
tal metaphysis. Briefly, the distal end of the analysis region
was chosen to be 0.105 mm proximal to the primary spon-
giosa in the marrow cavity. This assured that only trabecular
bone was analyzed. Starting at this image, a user-defined con-
tour was drawn to include only the marrow cavity and
exclude any cortical bone. User-defined contours were drawn
every 10 images (0.105 mm) and an automated morphing pro-
gram was used to interpolate the contours for all images in
between. A fixed, global threshold of 230 (1/1,000 gray scale)
corresponding to 321.6 mg of HA per milliliter was used to
distinguish trabecular bone from soft tissue and marrow. For
both analyses, a Gaussian low-pass filter was used (r ¼ 0.8,
support ¼ 1).
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Statistics and Image Editing
A two-tailed, homoscedastic t test was used to determine any
difference between control and experimental groups. Values
are reported as the mean 6 the standard deviation. p < .050
was considered statistically significant. p < .100 was consid-
ered to represent a nonsignificant trend. In images with
‘‘intact’’ and ‘‘deleted’’ bands lanes were cropped from the
same parent gel. Brightness and contrast were optimized
equally across all lanes for improved visibility.
RESULTS
Primary Bone Marrow Stromal Cells Express
Functional ObRb
Primary BMSCs were harvested from wild-type C57BL/6J
mice and analyzed for expression of leptin receptor mRNA at
passage two (P2). Consistent with previous reports in human
BMSCs [14] and mouse clonal MC3T3-E1 osteoblasts, [28]
both short-form ObRa and long-form ObRb leptin receptors
were expressed as the progenitor cells differentiated to mature
osteoblasts for 7, 14, or 21 days (Fig. 1A). As primary
BMSCs are a heterogeneous population that is contaminated
by cells of the macrophage lineage, we generated a mouse
model with floxed ObRb deletion driven by the LysozymeM
locus (LysMF/F) to disrupt ObRb function in macrophages
[30]. Cre-lox recombination is a tool that is used to mediate
site-specific recombination of genomic DNA [31]. DNA
sequences that are flanked by LoxP nucleotide sequences or
‘‘floxed’’ are susceptible to deletion and recombination by the
enzyme Cre recombinase. When expression of Cre is placed
under the control of a specific promoter, such as LysM, gene
deletion can be limited to the cell populations where that pro-
moter is expressed. In our experiments, the flox sites were
designed to flank exon 17 of ObRb. When probed with pri-
mers designed to surround this exon, cre-mediated deletion of
the segment was determined based on the appearance of a
shorter 200 bp PCR band when compared with the intact
646 bp band (Fig. 1B). Stimulation of marrow-derived mono-
cytes from these mice with 50 ng/ml macrophage colony
stimulating factor (M-CSF) for 2 days resulted in recombina-
tion of the ObRb locus in macrophages in vitro (Fig. 1C). As
expected, culture of primary BMSCs from LysMF/F mice
demonstrated that macrophage contamination of BMSC cul-
tures decreased with passaging of the cells (Fig. 1C). Primary
BMSCs (P2) derived from LysMF/F mice were stimulated
with 1,000 ng/ml leptin for 0, 5, 10, or 20 minutes and down-
stream phosphorylation of Stat3 (P-Stat3) was analyzed. In
response to leptin stimulation, rapid induction of P-Stat3 was
observed after 5–10 minutes that could be attributed to the
non-macrophage portion of the primary BMSC preparation
(Fig. 1D).
Knockout of ObRb in vitro Decreases
Mineralization and Increases Adipogenesis
of Primary Stromal Cells
To evaluate the significance of endogenous leptin production
in culture, primary BMSCs were harvested from long bones
of control mice harboring the ObRb LoxP mutation. Cells
were treated at P1 with adenovirus-expressing Cre
Figure 1. Primary BMSCs express functional ObRb. (A): PCR analysis of long-form (ObRb) and short-form (ObRa) leptin receptor. RNA from
C57BL/6J (WT) P2 BMSCs. (B): Diagram of amplified PCR products from intact or cre-recombined (deleted) genomic DNA. (C): LoxP recom-
bination in genomic DNA from whole bone marrow (WBM), primary Mac, and P1-P3 BMSC from LysMCreþF/F mice. (D): P-Stat3 induction
after 1,000 ng/ml leptin administration (n ¼ 3). Abbreviations: BMSC, bone marrow stromal cell; GAPDH, Glyceraldehyde 3-phosphate dehydro-
genase; Mac, macrophage; ObRb, long-form leptin receptor; WT, wild type.
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recombinase (AdCre) or a nonfunctional poly-L-poly-A
sequence (AdBlank) and monitored for ObRb gene deletion.
Complete recombination of the LoxP site occurred after
AdCre treatment (Fig. 2A,B: insets). Treated BMSCs were
harvested and replated at a density of 25,000 cells per square
centimeter in 12-well plates and induced to differentiate to-
ward osteoblasts. AdCre-treated cells exhibited significantly
less in vitro mineral apposition at day 7 of osteogenic culture
that was equalized by day 14 (Fig. 2A). This deletion study is
the converse of previous experiments that have added leptin
directly to primary BMSCs in vitro and observed an increase
in mineralization [15]. Similarly, primary ADSCs were har-
vested from para-lumbar and intra-abdominal fat pads and
treated with AdCre or AdBlank as described above. Ablation
of ObRb function increased the adipogenic differentiation of
the confluent cell monolayers by 99.8% 6 25% (Fig. 2B).
This is also consistent with previous results that have demon-
strated inhibition of adipogenesis in vitro by recombinant lep-
tin [32].
BMSCs Obtained From Mice With an Absence of
Total Body ObRb Signaling Show Increased
Mineralization Potential in vitro
Surprisingly, although the in vitro disruption of leptin signal-
ing resulted in reduced mineralization, primary BMSCs from
leptin-deficient Ob/Ob and ObRb-deficient Db/Db mice
showed a high mineralization phenotype. At day 14, minerali-
zation of Ob/Ob and Db/Db cultures was increased by 50.7 6
6.4% or 45.1 6 5.4% respectively (Fig. 3A). Addition of 100
ng/ml recombinant leptin to the medium failed to rescue the
high mineralization phenotype (Fig. 3A). Osteocalcin expres-
sion at day 14 was also increased by 2.9- 6 0.08-fold (Ob/
Ob) or 2.4- 6 0.23-fold (Db/Db) (Fig. 3B). Alkaline phospha-
tase activity was significantly higher per total protein in Ob/
Ob but not Db/Db cells (Fig. 3C).
Generation of Transgenic Mice Expressing Col2.3-
Cre or Col3.6-Cre and Harboring the ObRbF/F Site
To determine the physiologic relevance of the divergent in
vitro mineralization patterns, we generated osteoblast (Col2.3)
and MPC (Col3.6) cell-specific knockout mice. The Col3.6
promoter is active in osteoblast precursors, whereas the 2.3
promoter is active when cells differentiate to become osteo-
blasts [29]. Mice harboring the ObRbF/F site were mated with
Col2.3-Cre ObRbF/– or Col3.6-Cre ObRbF/– mice to generate
litters consisting of Cre-F/F, Cre-F/–, CreþF/–, and CreþF/F
mice in a 1:1:1:1 ratio. Breeding conformed to expected Men-
delian ratios, however, complete gene disruption was observed
in a significant number of female pups and some of the males
for both Col3.6-Cre and Col2.3-Cre litters (observation, not
quantified). This is consistent with previous reports of sporadic
germline recombination [33] when using the Col2.3 and Col3.6
promoters. Complete knockout (KO) mice were easily identi-
fied phenotypically by their frank obesity and genetically by
100% band excision in tail tip DNA (Supporting Information
Fig. 1A). Tissue analysis of genomic DNA revealed some
recombination in all tissues of 3.6CreþF/F mice with the highest
deletion rate in adipose, tendon, and calvaria (Fig. 4A). Con-
sistent with previous reports, the majority of in vitro primary
3.6CreþF/F BMSCs harbored the deleted form of the ObRb
locus [29] (Fig. 4B). We speculate that the background recom-
bination in 3.6CreþF/F whole tissues can be attributed to expres-
sion of Col3.6 in tissue-associated MPC or vascular endothelial
cells. Recombination in 2.3CreþF/F mice was highest in muscle,
calvaria, and whole marrow (Fig. 4A).
The gross phenotype of 2.3CreþF/F mice was identical to
2.3Cre controls. The 3.6CreþF/F mice demonstrated mild obesity
that remained statistically significant after approximately 12 weeks
of age (Fig. 4C). Mice were examined for alterations in fasting se-
rum chemistries including cholesterol, calcium, alanine amino-
transferase (ALT), albumin, alkaline phosphatase, amylase, blood
Figure 2. Knockout of ObRb in vitro decreases the mineralization of primary bone marrow stromal cells (BMSCs) and increases adipogenesis
of primary adipose-derived stromal cells (ADSCs). (A): Alizarin red stain and stain quantification of BMSCs treated with AdCre or AdBlank 800
MOI (n ¼ 3). (B): Adipogenesis, Oil Red O stain, of ADSCs treated with AdCre or AdBlank 400 MOI (n ¼ 4). Insets: Genomic DNA analysis
of LoxP recombination.
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urea nitrogen, creatinine, hemoglobin, phosphate, total bilirubin,
total protein, glucose, and leptin (Fig. 4D, 4E). The only signifi-
cant differences in these values between the 3.6Cre and 3.6Creþ F/
F mice were a slight increase in serum calcium (within normal
range), a small increase in total protein driven by an increase in al-
bumin and a significant elevation of serum leptin (Fig. 4D). Thus,
unlike the complete KO mice, 3.6Creþ F/F mice were not diabetic
and had no significant alterations in liver or kidney function. Next,
food intake of 42-week-old mice was monitored for 1 week. No
significant differences were observed between the three groups
(Data Not Shown).
Contrasting Bone Phenotypes of 2.3Cre1F/F
and 3.6Cre1F/F Mice
At 12 weeks, female 3.6CreþF/F mice maintained a 41% 6
5.3% body mass increase over controls compared with a
146% 6 6.2% body mass increase in the complete KO mice
(Fig. 5A). Femurs were dissected free of muscle and radio-
graphed at 32 kV for 45 seconds (Fig. 5B). Femoral microCT
analysis revealed no difference in trabecular parameters of the
2.3CreþF/F femurs (Fig. 5C). However, cortical parameters
showed a nonsignificant trend (p < .100) toward increased
bone volume and bone area (Fig. 5D). The only significant
change was a 1% decrease in cortical total volume mineral
density (Fig. 5D).
Because of the presence of significant differences,
femurs of 3.6CreþF/F mice were analyzed at both 12 and 42
weeks of age. At 42 weeks, femur length was increased by
0.78 6 0.02 mm (5.5% 6 0.16%) in male 3.6CreþF/F mice
when compared with 3.6Cre controls (Supporting Informa-
tion Fig. 1B). At both ages, trabecular parameters including
bone volume fraction (BVF) and mineral density of total
volume (MD of TV) were significantly increased by 58%–
61.9% and 65.5%–74%, respectively (Fig. 5C, Supporting
Information Fig. 1C). Increased cortical parameters at 12
weeks mimicked those present in complete KO mice with an
18.3% 6 1.7% and a 21.7% 6 2.2% increase in bone vol-
ume and total mineral content, respectively (Fig. 5D). The
decrease in femoral trabecular BVF and increased cortical
parameters of our spontaneous complete KO mice recapitu-
lates what has been reported previously for Ob/Ob mice [26]
(Fig. 5C, 5D).
Primary BMSCs From Mice 3.6Cre1 F/F Mice Have
Increased Osteoblast and Adipocyte Differentiation
Potential in vitro
To verify that deletion of ObRb in vivo results in an increased
differentiation in vitro, we harvested primary stromal cells
from both 3.6Control and 3.6Creþ F/F mice. Mineralization of
the BMSCs at P2 in vitro revealed a robust mineralization
Figure 3. BMSCs from Ob/Ob and Db/Db mice show increased mineralization. (A): Day 14 OM with or without 100 ng/ml leptin, alizarin red
stain, and quantification, P2 BMSCs (n ¼ 5–6). (B): Quantitative PCR for osteocalcin expression (n ¼ 3). (C): Alkaline phosphatase activity as
measured by conversion of p-nitrophenol phosphate to nitrophenol, normalized to total protein (n ¼ 3). Abbreviations: ALP, alkaline phosphatase;
Db, Db/Db leptin-receptor deficient mice; Ob, Ob/Ob leptin-deficient mice; OCN, osteocalcin; OM, osteogenic media; WT, wild type.
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phenotype that mimicked that of BMSCs from Ob/Ob and
Db/Db mice. Mineralization was increased by 422% 6 215%
at day 7 and 192% 6 17% at day 14 (Fig. 6A). Differentia-
tion of primary BMSCs also showed a 97.7% 6 23.1%
increase in adipogenic potential (Fig. 6B).
DISCUSSION
It is well-established that leptin acts primarily through the
hypothalamus to regulate weight gain through food intake
[2–4]. Generation of a mouse with conditional disruption of
the long-form leptin receptor gene in the MPC and osteoblast
has allowed us to begin to understand the physiologic contri-
butions of peripheral leptin in bone. We used a mouse with
LoxP sites flanking exon 17 of ObRb to critically evaluate
physiologic regulation of bone formation by peripheral leptin
in vitro and in vivo. To do this, three transgenic mouse lines
were generated with cell-specific KO of ObRb function using
the LysM, Col2.3, and Col3.6 promoters. Use of the Col2.3
and Col3.6 promoters is somewhat limited by high levels
(15%–50%) of germline recombination that decreases the
number of usable offspring [33] as well as nonspecific expres-
sion of Col3.6 in tendon, skin, and muscle [29]. However,
both promoters have previously been used successfully [34,
35] and an alternative promoter that drives reliable recombi-
nation in the mesenchymal precursor compartment without
affecting neighboring bone cells is not yet available.
The Col3.6 promoter is known to be expressed in multiple
tissues including tendon, skin, calvaria, and long bone [29].
Analysis with ROSA reporter mice shows widespread expres-
sion in the bone cavity that encompasses the osteocyte, osteo-
blast, and stromal fibroblast population with additional expres-
sion observed in some clustered areas of proliferative and
hypertrophic chondrocytes [29]. Adipose tissue was not ana-
lyzed in this previous publication, although our current study
reveals high levels of recombination in the fat pads (Fig. 4A).
As the Col3.6 promoter mediates LoxP recombination in
osteoblasts, adipocytes, and some chondrocytes, we believe
that it likely deletes the gene a precursor population for these
lineages, the MPC. BMSC from Col3.6-Cre mice crossed
with ROSA Cre-reporter mice in low-density colony forming
unit-fibroblast (CFU-F) cultures show high expression of Cre-
recombinase in primitive colonies which is additional evi-
dence that Col3.6 forces recombination at an early MPC-like
level [29]. Thus, we propose that recombination driven by
Col3.6-Cre is one method that can be used to study effects of
gene deletion on MPC function in vivo. However, it is still
possible that an unidentified population of neurons expresses
Col3.6 and that ObRb deletion in these cells is contributing to
the 3.6Creþ F/F mouse phenotype. When leptin receptors are
completely deleted in the hypothalamus in vivo, this results in
decreased length and trabecular bone of the femur [26]. As
the 3.6CreþF/F mice have longer femurs with increased
Figure 4. Characterization of mice expressing Col2.3-Cre or Col3.6-Cre and harboring the ObRbF/F site. (A): Representative PCR of tissue
genomic DNA. (B): PCR of WBM and P1-P3 BMSCs from 3.6CreþF/Fmice. (C): Representative mouse photographs. (D): Serum leptin ELISA
(n ¼ 6). (E): Col3.6 mouse serum chemistries (n ¼ 3–6). Abbreviations: ALT, alanine aminotransferase; BMSC, bone marrow stromal cell;
BUN, blood urea nitrogen; WBM, whole bone marrow.
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trabecular bone, it is not yet clear how nonspecific brain
recombination would contribute to the bone phenotype. How-
ever, future studies will continue to explore this possibility.
Col2.3 promoter expression is more restricted and shows dele-
tion primarily in more differentiated osteoblasts [29]. We
have used the above premise to explore the contrasting in
vitro mineralization phenotypes found in leptin-signaling defi-
cient BMSCs that were generated in vitro (AdCre) or in vivo
(Ob/Ob and Db/Db) (Figs. 2, 3).
When determining the ability of Ob/Ob and Db/Db cells
to mineralize in vitro, an unanticipated finding was that de-
spite decreases in femoral trabecular bone content in vivo [26]
Figure 5. 2.3CreþF/F, but not 3.6CreþF/F mice show increased trabecular bone. (A): Mass of mice (n ¼ 3–6). (B): Representative faxitron x-ray
at 32 kV, 45-second of femurs. (C, D): Percent change in trabecular or cortical bone parameters as determined by microCT (n ¼ 3–6). Abbrevia-
tions: KO, knockout; MD of TV, mineral density of total volume; mo, month.
Figure 6. Knockout of ObRb in mesenchymal progenitor cells (MPCs) in vivo with Col3.6-Cre results in increased in vitro mineralization and
adipogenic potential. (A): Mineralization, alizarin red stain, and quantification, P2 bone marrow stromal cells (BMSCs) (n ¼ 3). (B): Adipogene-
sis, oil red o stain, P2 BMSCs (n ¼ 3). Insets: Genomic DNA analysis of LoxP recombination.
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(Fig. 5C) the cells actually mineralized more than their con-
trols in vitro (Fig. 2A). This was matched by increases in
osteocalcin expression and for Ob/Ob, increases in alkaline
phosphatase activity (Fig. 2B, 2C). ALP activity is variable in
murine BMSC cultures and we do not yet understand the sig-
nificance, if any, of the nonsignificant differences between wild
type (WT) and Db/Db BMSCs. This finding of high minerali-
zation was initially assumed to be due to unknown systemic
complications of diabetes and obesity. Addition of recombi-
nant leptin did not reduce the mineralization of the cells to
baseline levels (Fig. 2A) implying that the starting population
derived from Ob/Ob mice is unique when compared with
WT. Previous publications have shown that leptin is able to
enhance mineralization at higher concentrations (0.6–1.2 lg/
ml) [15]. The systemically healthy 3.6CreþF/F ObRb mouse
model which exhibited an opposite in vivo phenotype of
increased trabecular BVF and bone mineral density (BMD) in
the femur (Fig. 5C) also showed increased mineralization
potential in vitro similar to the Ob/Ob and Db/Db mice (Fig.
6A). This suggests that in vivo the systemic environment is
driving differentiation of the MPCs in opposite directions in
the Ob/Ob (increased medullary fat) and 3.6CreþF/F (increased
trabecular bone) mice. Despite these differences in vivo, cul-
ture of the cells in vitro revealed uniform increased sensitivity
to osteoblast differentiation. In contrast, deletion of ObRb in
cultured and passaged P2 BMSCs in vitro decreased minerali-
zation (Fig. 2A). We believe that this in vitro deletion occurs
when mesenchymal lineage cells are fundamentally very dif-
ferent and more differentiated than the in vivo deletion that
occurs in primitive in MPC of Ob/Ob, Db/Db and 3.6CreþF/F
mice. Although an absence of leptin signaling in primitive
cells results in MPC with enhanced differentiation potential,
ObRb disruption in differentiated cells in vitro is inhibitory to
osteoblast differentiation but promotes adipogenic differentia-
tion. As observed with the 2.3CreþF/F mouse and one previous
publication [17], inhibition of leptin’s actions on osteoblasts
does not appear to be physiologically relevant to trabecular bone
parameters during states of healthy equilibrium in vivo (Fig. 5C).
Even in the presence of intact leptin signaling, obesity can
have significant effects on bone cell function in vitro and bone
mass in vivo [36, 37]. Studies that have analyzed bone parame-
ters in mice due to diet induced obesity observed increases in
cortical parameters of the femur [36] with no change [36] or
decreases [37] in trabecular parameters. These studies observed
changes in obese mice of age 14–25 weeks that were approxi-
mately 32–38 g. Despite being of comparable age and body
mass to the diet-induced obese mice, our 3.6CreþF/F mice pre-
sented with statistically significant increases in trabecular bone
parameters instead of decreases (Fig. 5C). Consistent with pre-
vious results [36], we also observed cortical changes in our
3.6CreþF/F mice at 12 weeks that failed to persist and equalized
by 42 weeks (Fig. 5D, Supporting Information Fig. 1C). Thus,
we conclude that the trabecular bone phenotype is due to
ObRb deletion and not increased load bearing.
As systemic leptin is increased in the 3.6CreþF/F animals
due to adipose accumulation, one must also consider the
effects of leptin on osteoclast function. It is possible that the
high bone mass observed in these animals is related to inhibi-
tion of osteoclast differentiation or activity. However, in vivo
KO of ObRb in osteoclast precursor macrophages with the
LysM-Cre promoter did not change body mass or bone pa-
rameters at 12 weeks (data not shown). In addition, published
data do not support a consistent role for leptin in mature
osteoclast function. For example, although Ob/Ob and Db/Db
mice have over twofold increase in osteoclast number, the
excretion of urinary deoxypyridinoline crosslink, a biochemi-
cal marker of bone resorption, was not impaired when com-
pared with controls [7]. Conversely, leptin deficient rats have
increased osteoclast surface, but no increase in numbers [38].
Isolation of primary bone marrow osteoclast progenitors from
leptin-deficient mice showed no deficiency in osteoclast dif-
ferentiation or their ability to form resorption lacunae on den-
tin [7]. Other in vitro studies demonstrated that leptin partially
inhibits osteoclastogenesis of primary mouse marrow cultures
but did not affect bone resorption of mature osteoclasts [39].
CONCLUSIONS
Based on our data we propose a working model for peripheral
leptin regulation of bone mass that includes divergent mecha-
nisms depending on the differentiation state of the MPC (Fig.
7). Generally, it is thought that a factor that controls MPC
differentiation to adipocytes will inhibit differentiation toward
osteoblasts and vice versa. However, in some situations, a fac-
tor may block differentiation of primitive MPCs without
regard for the downstream possibilities, in effect maintaining
stemness. Here, we demonstrate that leptin may be one of the
factors that functions to maintain MPCs in an undifferentiated
state. Thus, in mice with leptin signaling deficient MPC there
is enhanced bone formation and increased adipogenesis, and
cells in vitro show increased differentiation to these fates.
Future studies will pursue this hypothesis and work to
uncover any potential Col3.6 expressing neurons that may
contribute to the bone and metabolic phenotype. Although we
do not yet understand the full implications of this finding,
there are multiple clinical scenarios that should be tested to
uncover its relevance. For example, it has been previously
reported that sites with high marrow fat content (and thus
higher local leptin concentration) have a decreased rate of
bone turnover [40]. It is possible that leptin’s inhibition of
MPC differentiation may play a role in this process. Or, per-
haps limited fracture healing potential in obese individuals
[41] with increased systemic leptin may be related to leptin’s
limitation of de novo mesenchymal activation, osteoblast
recruitment, and subsequent matrix synthesis. In the future,
we hope to address these questions and expand our molecular
understanding of leptin’s regulation of MPC function. In sum-
mary, we conclude that although the effect of leptin on
Figure 7. Peripheral model of leptin’s action on MPCs and osteo-
blasts. Leptin (a) helps to maintain MPCs in an undifferentiated state
and (b) promotes differentiation and mineralization of in vitro preosteo-
blasts and osteoblasts. Abbreviation: MPC, mesenchymal progenitor cell.
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mature osteoblast function may not be physiologically signifi-
cant in vivo, leptin has previously unrecognized peripheral
roles in bone that include regulation of MPC differentiation.
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